Fundraising FoxSan Francisco · Pre-Seed–Late Stage · 13 people tracked
Also known as AWESOME ENABLERS, L.L.C. · MBC FII MANAGEMENT, LLC · Mission Wealth Management, Lp
Find your way into Mission Bay Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Bill Hoffman to introduce you to Jon Root
You →Bill · together at Inari Medical →Jon
Ask Jamie Chen to introduce you to Robert Blazej
You →Jamie · together at MBC Biolabs →Robert
Ask Sam Okafor to introduce you to Brook Byers
You →Sam · together at Kleiner Perkins →Brook
- Wende Hutton178 people can intro you
- Peter Parker167 people can intro you
- Vivian Dang125 people can intro you
Sign up to find every way you can get introduced to Mission Bay Capital
- Your email: who you already know at Mission Bay Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Mission Bay Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Mission Bay Capital aims to help entrepreneurial scientists turn ideas into successful companies, viewing startups as an efficient engine for positive change. It provides critical early-stage capital to prove out technologies at a point when other investors are hesitant. Through its MBC BioLabs incubator, the firm offers state-of-the-art laboratory facilities so startups can begin experiments immediately, helping founders operate efficiently. It further supports portfolio growth through a network of advisors, industry partners, university colleagues, and co-investors. The firm concentrates on science-driven ventures tackling oversized problems including chronic diseases and global environmental challenges.
Source: firm website, verified Sep 29, 2026.
Team · 13 people
from the firm's website & curated & public directories
Founder mafia
3 people who came through Mission Bay Capital went on to found or lead other companies.
What they invest in
from 30 of 37 portfolio companiesBiotech ×25Medical Devices ×12Healthtech ×11Deep Tech ×6AI & Machine Learning ×2Climate Tech ×2Consumer ×2FoodTech ×2
HQs:United States×27
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×82 founders×23 founders×34+ founders×3
Where their founders studiedfrom 12 founders with education data
Harvard University ×3University of California, Berkeley ×2
What their founders studiedfrom 12 founders with field-of-study data
Life Sciences ×6Chemistry ×2
Where their founders worked beforefrom 14 founders with career history
Stanford University ×2
Investments · 37 tracked
founders shown can be your intro pathBy year:2023 · 12020 · 12018 · 22016 · 22015 · 22012 · 19 dated
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalGV (Google Ventures)Mission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)inRobert Weisskoff(Director)in
Co-investorsAliment CapitalAvego BioScience CapitalF-Prime CapitalIA Seed VenturesLifeSci Venture PartnersMission Biocapital+3 more
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)inAnnie Mitsak(Director)in
Co-investorsCure VenturesMission Biocapital
Nobell Foods produces plant-based dairy cheese made from soybean plants engineered to grow casein protein, working with Midwest farmers.
BiotechClimate TechConsumerFoodTechSan Francisco, US
Magi Richani(Founder/CEO)in
BoardChris Rivest(Director)Vijay Pande(Director)inKyle Vogt(Director)
Co-investorsAgFunderAndreessen HorowitzDCVC (Data Collective)Mission BiocapitalUnovis Asset ManagementY Combinator+7 more
Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents.
Deep TechHealthtechMedical DevicesSan Francisco, US
Co-investorsBaruch Future VenturesBerkeley CatalystMission Biocapital
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsEmles Venture PartnersGoAhead VenturesMission BiocapitalRA CapitalY CombinatorAlexandria+8 more
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsAisling CapitalEcoR1 CapitalEvolution VC PartnersMission Biocapital
Bolt Threads was a manufacturer of biomaterials for personal care formulations.
BiotechNew MaterialsFoxboro, US
Ethan Mirsky(Executive Officer)David Breslauer(Executive Officer, Director)Daniel Widmaier(Executive Officer, Director)
BoardJerry Fiddler(Director)Steven Vassallo(Director)inJim Kim(Director)
Co-investorsKicker VenturesKyber Knight CapitalMission Biocapital8VCBaillie GiffordEast West Capital Limited+4 more
BiotechLafayette, US
Peter Emtage(Executive Officer)inGreg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)
Co-investorsKleiner PerkinsMission BiocapitalOUP (Osage University Partners)
HealthtechHayward, US
GUY DIPIERRO(Director)inALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsCota CapitalEmergent Medical Partners, LLPFountain Healthcare PartnersKaiser Permanente Ventures5AM VenturesCanaan Partners+2 more
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission BiocapitalNextech Invest+3 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersMission BiocapitalOlive Tree Capital+4 more
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk.
BiotechHealthtechMedical DevicesSan Francisco, US
Brian Shoichet(Director)Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)in
BoardDouglas Crawford(Executive Officer, Director)in
Co-investorsMenlo VenturesMission BiocapitalKleiner Perkins
BiotechDeep TechHardware
Co-investorsClaremont Creek VenturesMission BiocapitalSignet Healthcare Partners
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesChiesi VenturesCTI Life Sciences Fund L.P.Mission BiocapitalRemiges Ventures, Inc.RiverVest Venture Partners+5 more
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Clara, US
Jay Trautman(President & CEO, Co-Founder)inChris Freudiger(Chief Technology Officer, Co-Founder)inChristian Freudiger(Director)inXiaoliang Xie(Director)
BoardDoug Crawford(Director)in
Co-investorsBerkeley CatalystMission Biocapital
Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.
Creator EconomyMarketing TechSaaS
Nathan Barry(Founder + CEO)in
Co-investorsAUTHENTIC VENTURESBrighter CapitalExpaMission BiocapitalWAGMI VenturesOceans Ventures+1 more
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)in
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalForesite CapitalMayfield Fund+10 more
Targeting mitochondria for neurodegenerative disease therapies.
BiotechNew York, US
Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)
BoardJohannes Fruehauf(Director)
Co-investorsMission BiocapitalPfizer Venture Investments
MPM Capital is a venture capital and life sciences investment firm that backs companies in biotech, therapeutics, and healthcare innovation, with a focus on translating scientific research into transformative medicines and treating severe diseases.
Biotech
Ansbert Gadicke(Chairman)inChris Bardon(Managing Partner)in
Berkeley, US
Co-investorsAutodesk FoundationAVA AngelsBerkeley SkyDeck FundCRV (Charles River Ventures)Melbourne Accelerator Program (MAP)Moonhill Capital+1 more
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsDementia Discovery FundMission BiocapitalSofinnova PartnersSV Health InvestorsAbbVie
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova VenturesOrbiMedSofinnova Venture Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesSR One Capital ManagementNew Leaf Venture PartnersOrbiMed+1 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission BiocapitalMitsui Global Investment+7 more
Symbiome develops skin microbiome-based wellness products that restore ancestral skin health through proprietary fermentation and Amazonian botanical ingredients.
ConsumerHealthtechWellness & FitnessSan Francisco, US
Larry Weiss(Executive Officer, Director)Adam Klausner(Executive Officer)Vicki Levine(Executive Officer, Director)
BoardAdam D'Augelli(Director)in
Co-investorsBold Capital PartnersMission BiocapitalGISEV Family OfficeTrue Ventures
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
BiotechDeep TechMedical DevicesCambridge, US
Co-investorsMission Biocapital
Wildtype grows salmon directly from fish cells using cellular agriculture, allowing production of seafood without wild-caught or farmed fish.
BiotechClimate TechFoodTechSan Francisco, US
Justin Kolbeck(Executive Officer, Director)inArye Elfenbein(Director)in
.jpg)
BoardJohn Melas-Kyriazi(Director)
Co-investorsBay Bridge Ventures ClimateCRV (Charles River Ventures)Maven VenturesMission BiocapitalRoot Ventures Manager, LlcS2G Investments+18 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alpine RoadsAmbagon TherapeuticsAvexegenCalitheraGraphwearLogicSymic BiomedicalViewPoint Therapeutics
Exits · 3
2 IPOs · 1 acquisitionsAlectorNASDAQ: ALECCaribou BiosciencesNASDAQ: CRBUFluxionacq. by Cell Microsystems
Portfolio news
latest coverage across their companiesDren Bio · biospace.com · Mar 2, 2026
Alessa Therapeutics · alessatherapeutics.com · Oct 21, 2025
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Mission Bay Capital IIILPs: The Regents of the University of California | 2018 | — | 21.8% | 2.11x | 0.28x |
| Mission Bay Capital IILPs: The Regents of the University of California, Sobrato Family Foundation | 2015 | — | 14.7% | 2.35x | 0.98x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Mission Bay Capital made?
- Mission Bay Capital has 37 tracked investments, 3 of which have exited.
- What stage does Mission Bay Capital invest at?
- Mission Bay Capital invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What sectors does Mission Bay Capital focus on?
- Mission Bay Capital focuses on Biotech, Climate Tech, Deep Tech, Healthtech, Medical Devices.
- Where is Mission Bay Capital located?
- Mission Bay Capital is headquartered in San Francisco, US.
- Who does Mission Bay Capital co-invest with?
- Mission Bay Capital most often shares deals with Mission Biocapital, Berkeley Catalyst, OUP (Osage University Partners), among 78 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Safar Partners is an early-stage technology investment firm that backs startups spun out of leading research universities, primarily MIT, Harvard, and the University of Rochester.